CMAB809 (trastuzumab biosimilar)
/ Mabpharm Limited
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 13, 2020
Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers
(clinicaltrials.gov)
- P1; N=72; Completed; Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd; Recruiting ➔ Completed; Trial completion date: Aug 2020 ➔ Nov 2019; Trial primary completion date: May 2020 ➔ Nov 2019
Clinical • Trial completion • Trial completion date • Trial primary completion date
August 08, 2019
Pharmacokinetic, Safety and Immunogenicity Study of CMAB009 and Herceptin in Healthy Volunteers
(clinicaltrials.gov)
- P1; N=72; Recruiting; Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd
Clinical • New P1 trial
1 to 2
Of
2
Go to page
1